Grilinctus-BM

Method of action: Expectorant

Treatment option:

Medically reviewed

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Grilinctus-BM

Property	Description
Active Ingredients	Bromhexine and Terbutaline
Form	Oral liquid (Syrup) and Tablet
Pharmacological Class	Expectorant (Combination Mucolytic Agent and Bronchodilator)
Common Type	Synthetic Combination Medicine
Route of Administration	Oral

What Type of Medicine is Grilinctus-BM?

Grilinctus-BM is a combination medicine classified within the overall therapeutic group of Expectorants, designed for oral administration as either a syrup or a tablet. This medication is synthetic in origin and is specifically formulated to address two distinct problems often associated with a productive cough: excessive, thick mucus and constricted air passages. The specific combination is frequently prescribed for pediatric patients due to the availability of its distinct oral liquid form. As a combination product, it is fundamentally different from a single-ingredient cough suppressant, which only aims to quiet the cough reflex.

Active Components: Bromhexine and Terbutaline

The effectiveness of Grilinctus-BM is based on its two active ingredients [INN]: Bromhexine and Terbutaline. Bromhexine is officially recognized as a mucolytic agent used to thin and break down the tough, sticky phlegm in the airways, making it easier to cough out. The second component, Terbutaline, belongs to the class of beta2-adrenergic agonists and functions as a fast-acting bronchodilator. This classification means the drug helps widen the air passages to ease breathing. Terbutaline's inclusion is clinically recognized for its efficacy in relaxing the smooth muscles of the bronchioles, a crucial step in managing restrictive breathing.

What is the General Purpose of Grilinctus-BM?

The general purpose of Grilinctus-BM is to provide dual-action relief that facilitates smoother breathing and more effective airway clearance. This is achieved by the complementary action of the two components: the mucolytic action loosens the mucus, while the bronchodilator action relaxes the airway muscles to widen the breathing passages. Ultimately, this coordinated effect helps the patient to comfortably and productively expel congestion from the chest, such as in a typical scenario involving a persistent, chesty cough following a respiratory infection.

What side effects are possible with Grilinctus-BM?

Possible Side Effects and Safety Information

The safety profile for this combination medicine, which contains the bronchodilator Terbutaline and the mucolytic Bromhexine, is classified based on officially documented adverse reactions from government regulatory sources.

Frequency-Classified Adverse Reactions

Adverse effects are categorized by frequency, with the most common reactions related to the sympathomimetic component, Terbutaline:

Very Common: Tremor and Headache.
Common: Tachycardia (increased heart rate), Palpitations, and Hypokalaemia (low serum potassium levels).
Uncommon: Gastrointestinal disturbances such as Nausea, Vomiting, Diarrhoea, and Upper abdominal pain (Bromhexine-related).

System-Organ-Class and Serious Reactions

The officially listed effects involve several systems, including the Nervous System, Cardiac Disorders, and Metabolism and Nutrition. Rare but clinically significant adverse reactions that are documented in regulatory labeling include the risk of Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson syndrome, associated with Bromhexine. Rare reports of Myocardial Ischaemia (heart oxygen deprivation) and Seizures are also associated with the Terbutaline component, which are listed as serious adverse events.

Population-Specific Safety Considerations

Regulatory documentation specifies that caution is required in patients with certain pre-existing conditions. These include patients with Ischemic Heart Disease or other Cardiovascular Disorders, and patients with Diabetes Mellitus (due to the potential for transient increases in blood glucose). Safety statements also advise caution for use during Pregnancy and in patients with Renal or Hepatic Impairment.

Safety-Related Restrictions

This medication is officially contraindicated in individuals with a known hypersensitivity to either active substance. It is also restricted from use in patients with pre-existing Ischemic Heart Disease or significant risk factors for it, as defined in regulatory labeling.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory information regarding an overdose of this combination medicine primarily focuses on the effects of the bronchodilator component. All overdose statements and emergency actions described are based strictly on government regulatory documents.

Documented Manifestations and Severe Outcomes

Overdose manifestations are classified as signs of excessive sympathetic nervous system stimulation. Documented clinical signs include tachycardia (rapid heartbeat), palpitations, tremor (uncontrollable shaking), anxiety, and headache. Gastrointestinal manifestations such as nausea and vomiting are also listed.

Severe outcomes documented in regulatory labeling include severe cardiac arrhythmias, seizures (convulsions), and profound hypotension. Critical metabolic findings requiring urgent management are hypokalemia (low potassium) and hyperglycemia.

Mandated Emergency Action and Management

In any suspected overdose situation, regulatory guidance mandates that a person seek immediate medical attention. Regulators explicitly require that emergency services be contacted immediately if the individual has collapsed, experienced a seizure, has trouble breathing, or cannot be awakened.

Official management procedures involve providing symptomatic and supportive treatment with continuous monitoring of vital signs, ECG, and electrolytes. A cardioselective beta-receptor blocking agent is cited as the preferred intervention; however, its administration is directed to be conducted with caution due to the underlying risk of bronchospasm.

Therapeutic Uses of Grilinctus-BM

What Grilinctus-BM Treats: Main Uses and Benefits

The therapeutic domain of Grilinctus-BM is focused on conditions where short-term symptomatic assistance is needed for obstructive airway conditions. This medicine is generally used to help address the symptoms of wheezing and chest tightness caused by the narrowing of the air passages (bronchospasm), as well as the distress from excessive, thick, tenacious mucus. Agents in this class are recognized therapeutic tools for managing asthma and COPD.

The combination is commonly applied in clinical settings that involve acute or unstable symptom patterns associated with Bronchial Asthma, Chronic Bronchitis, COPD, and bronchopulmonary disorders. The combination may assist with symptomatic support for both adult and pediatric patients experiencing a challenging combination of symptoms. The combination's use contributes to improved comfort during periods of heightened symptoms.

Quick Fact: Relief for Congested Breathing

Grilinctus-BM assists with maintaining functional stability by promoting a more productive cough that efficiently clears the chest, which contributes to easing the overall symptom load related to congestion and constricted breathing.

Regulatory References

Bronchodilators: StatPearls - NCBI Bookshelf - NIH

Eligibility and Restrictions for Use

Absolute Contraindications

The medicine is contraindicated and must not be used by patients with a known hypersensitivity to either Bromhexine, Terbutaline, or any excipient in the formulation. Due to the Terbutaline component, use is also prohibited for individuals with severe cardiovascular disorders, including hypertrophic cardiomyopathy. Furthermore, the oral Terbutaline component is specifically contraindicated by regulators for pregnant women to treat or prevent preterm labor.

Age and Reproductive Status

Use is contraindicated in children under 2 years of age. While approved for adults, use in elderly patients requires regulatory caution. Grilinctus-BM is generally not recommended for women during the first trimester of pregnancy or for breastfeeding mothers.

Restrictions and Conditional Use

Conditional eligibility applies to several patient populations. Use of this medicine requires explicit caution in patients diagnosed with severe hepatic (liver) impairment or severe renal (kidney) impairment due to potential clearance concerns. Caution is also required for individuals with conditions sensitive to sympathomimetic agents, such as thyrotoxicosis, diabetes mellitus, and a history of gastric ulceration or convulsive disorders.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory documents structure the product's interaction profile primarily around the Terbutaline (beta2-agonist) component, defining specific restrictions and requirements for caution based on pharmacodynamic effects.

Officially Documented Interaction Categories

Interaction Type	Interacting Substances / Classes
Antagonism of Effect	Non-selective beta-blockers (may inhibit bronchodilation)
Cardiovascular Potentiation	MAOIs, TCAs, and other sympathomimetic agents (co-administration generally not recommended)
Electrolyte Risk	Diuretics (thiazide/loop), Xanthines, and Corticosteroids (may potentiate hypokalemia)
Contraindicated Use	Oral Terbutaline is contraindicated for use in tocolysis (delaying labor).
Increased Antibiotic Penetration	Antibiotics (Bromhexine may enhance their penetration into bronchial secretions)

Co-administration with non-selective beta-blockers may inhibit the effect of Terbutaline, and is not recommended. Caution is necessary when combining with agents that increase the risk of hypokalemia, as this can increase the risk of arrhythmia when combined with substances such as digitalis glycosides. Furthermore, co-administration with other sympathomimetic agents is generally discouraged due to the potential for combined cardiovascular effects. Clearance of the Bromhexine component may be reduced in patients with severe hepatic or renal impairment.

Mechanism of Action

How Grilinctus-BM Works

Influence on Airway Smooth Muscle Tone

One mechanistic component acts as a selective boldsymbolbeta2-adrenergic receptor agonist. This interaction occurs at receptors primarily located on the smooth muscle cells surrounding the air passages (bronchi and bronchioles). Receptor binding initiates a downstream intracellular signaling cascade, ultimately decreasing the calcium ions available for muscle contraction. This action results in the relaxation of airway smooth muscle and a subsequent increase in the lumen diameter of the air passages. This physiological change causes a decreased resistance against gas movement in the airways.

Alteration of Secretion Viscoelasticity

The second mechanistic component functions as a mucolytic agent. This agent chemically interacts with the complex molecular structure of the respiratory tract secretions, specifically targeting and disrupting the disulfide bonds that maintain high viscosity and adhesiveness. The resulting molecular depolymerization leads to a reduction in secretion viscosity. This physiological effect promotes the movement and expulsion of secretions from the respiratory tract by rendering them less resistant to the body’s clearance mechanisms.

Dosage and Administration Information

How Grilinctus-BM is Used

The usage of this combination medicine, containing Terbutaline and Bromhexine, is strictly defined by prescribing information concerning the approved route, dosage limits, and frequency of administration.

Official Administration Guidelines

Guideline	Instruction
Route of Administration	Oral (by mouth) for both the liquid and tablet formulations
Standard Frequency	Three times daily (TID), typically administered at approximately 6-hour intervals during waking hours.
Timing with Food	May be taken with or without food.
Preparation	The oral solution requires the use of an accurate, calibrated measuring device to ensure the correct dose volume is delivered.

Dosing Limits and Special Populations

Adult Dosing: The typical starting dose for the Terbutaline component in adults is 5 mg per administration. The maximum total daily dose for the Terbutaline component must not exceed 15 mg within a 24-hour period.

Adolescent Dosing: For adolescents aged 12–15 years, the maximum total dose for the Terbutaline component is restricted to 7.5 mg within a 24-hour period, reflecting a reduced dose regimen compared to adults.

Organ Impairment: Dose adjustments may be necessary for patients with severe hepatic or renal impairment, as the clearance of the Bromhexine component's metabolites may be reduced in these circumstances.

Procedural Rule: If symptoms worsen or fail to improve, the dose or frequency must not be increased beyond the maximum labeled amount; immediate re-evaluation by a health professional is the prescribed action.

Recent Clinical Evidence

Grilinctus-BM: Recent Clinical Evidence

Grilinctus-BM is a pharmaceutical preparation that typically contains a combination of Terbutaline and Bromhexine. These components are categorized as a beta2-adrenergic agonist (bronchodilator) and a mucolytic agent, respectively. The combination is indicated for the symptomatic management of productive cough associated with various respiratory conditions.

Role of Active Components

Component	Drug Class	Primary Action in the Context of Cough
Terbutaline	beta2-Agonist (Bronchodilator)	Relaxes the smooth muscles of the bronchial tubes, which may support the widening of air passages.
Bromhexine	Mucolytic Agent	Functions to reduce the thickness and viscosity of excessive mucus in the airways.

Research Findings

Clinical studies have explored the combined use of bronchodilators and mucolytics in individuals experiencing cough with mucus, such as those with bronchitis, bronchial asthma, and Chronic Obstructive Pulmonary Disease (COPD). The evidence suggests that the inclusion of an agent like Terbutaline may help in improving airflow, while Bromhexine's action may facilitate the clearance of secretions from the respiratory tract.

Research has generally observed that this dual-action approach may provide support for easier expectoration and relief from associated chest congestion. The effect of Bromhexine has been noted to potentially increase the flow and reduce the stickiness of bronchial secretions. When used as part of a therapeutic regimen, the combination is studied for its ability to address both narrowed airways and the presence of thick phlegm. These findings underscore a role in supportive care, but they are not presented as curative for the underlying respiratory diseases. The overall tolerability profile in clinical use has been assessed as generally acceptable, though potential adverse effects, such as tremor and nervousness linked to the beta2-agonist, are commonly noted.

Frequently Asked Questions (FAQ)

Common questions about Grilinctus-BM (FAQ)

Q: What is the expected onset time for cough relief after taking Grilinctus-BM?

According to professional product information, the cough relief effect from the syrup formulation is cited to begin as quickly as 5 to 10 minutes of being taken. This is a factual description related to the action of the bronchodilator component.

Q: How long does the effect of Grilinctus-BM typically last?

Official documents regarding the pharmacokinetics of the active ingredients state that the effects are maintained for an extended period. The duration of effect is generally reported to last approximately 10 hours on average.

Q: Can Grilinctus-BM be taken with common pain relievers?

Regulatory warnings describe a potential interaction regarding the use of this medicine with some common pain relievers. Non-steroidal anti-inflammatory drugs (NSAIDs) may increase the risk of high blood pressure when combined with the Terbutaline component.

Q: Is Grilinctus-BM described as safe to take before operating machinery?

Official warnings exist regarding driving or operating heavy machinery. This information is provided because the medicine may cause side effects such as dizziness or drowsiness that could potentially affect alertness and coordination.

Q: Are there any known issues with Grilinctus-BM and glaucoma?

The requirement for caution is noted in regulatory documents for individuals diagnosed with glaucoma. This is related to the action of the sympathomimetic component, Terbutaline, which is described as potentially affecting this condition.

Q: Can Grilinctus-BM affect sleep quality?

Official product information indicates that the medicine may affect sleep quality. Potential adverse effects include both difficulty falling asleep (insomnia) and, conversely, drowsiness or excessive sleepiness.

Q: What happens if a scheduled dose of Grilinctus-BM is missed?

Official guidelines describe that a missed dose is to be taken as soon as remembered, unless it is near the time of the next scheduled dose, in which case the guideline is to skip the missed dose entirely. This protocol is intended to avoid taking too much medicine too closely together.

Q: What are the typical signs of taking more Grilinctus-BM than intended?

According to regulatory warnings, signs of taking more than the intended amount may include serious effects related to the heart. These symptoms can include a fast heart rate, chest pain, uncontrollable tremor (shaking), dizziness, or even seizures.

Q: Is Grilinctus-BM categorized as a prescription-only or over-the-counter medicine?

The combination product's regulatory status is typically determined by its active ingredients. Because the component Terbutaline is generally classified as a Prescription Only (Rx Only) medicine, the final product is usually subject to the same regulatory oversight.

Q: Can the use of Grilinctus-BM lead to a dry mouth?

Yes, official safety information documents note that dry mouth is a documented side effect. This effect is associated with the mechanisms of action of both active ingredients.

Q: Does Grilinctus-BM contain sugar, which might affect diabetic patients?

Formulations of the syrup vary, and while some may contain sugar, many specific formulations are made available as sugar free. This information is relevant for individuals managing diabetes mellitus.

Q: Does taking Grilinctus-BM commonly cause dizziness or lightheadedness?

Yes, regulatory documents list dizziness or lightheadedness among the documented side effects. This effect is commonly associated with sympathomimetic medicines.

Q: Are there any known interactions between Grilinctus-BM and caffeine?

Official patient advice includes a warning about the use of stimulants such as caffeine and energy drinks. These substances may potentiate (increase the strength of) the sympathomimetic effects of the Terbutaline component, which can lead to increased nervousness or heart rate.

Q: Can Grilinctus-BM cause changes in appetite?

The official safety data does not list changes in appetite as a standard side effect. However, loss of appetite is reported as a potential sign that may occur in cases of accidental overdose.

Q: What general safety information is available about Grilinctus-BM and high blood pressure?

Official safety statements specify that caution is required for individuals with pre-existing high blood pressure (hypertension). This is necessary due to the cardiovascular effects of the beta2-agonist component, Terbutaline.

Q: Does Grilinctus-BM have any known effects on liver function tests?

Official adverse reaction reports associated with the Bromhexine component include documentation of elevated liver enzymes. Liver enzymes are specific markers measured in liver function tests.

Q: How long after stopping Grilinctus-BM does the medicine stay in the body?

Information on the pharmacokinetics of the active ingredients indicates their clearance time from the body. The terminal elimination half-lives range from approximately 8 to 16 hours, providing an estimate of the medicine's clearance time.

Q: Is it common to feel jittery or anxious after taking Grilinctus-BM?

Yes, official safety information indicates that the most common adverse reactions are related to the beta2-agonist component. These include frequently reported effects such as tremor (shaking) and nervousness.

Q: What evidence supports the use of Grilinctus-BM for chronic cough conditions?

Studies and official documentation indicate this medicine is used for the symptomatic management of cough. It is specifically indicated for cough associated with chronic respiratory conditions such as Chronic Obstructive Pulmonary Disease (COPD) and chronic bronchitis.

Q: What is the difference between a centrally-acting cough suppressant and the components of Grilinctus-BM?

The components of Grilinctus-BM are a bronchodilator and a mucolytic agent. This formulation is fundamentally different from a centrally-acting cough suppressant, which works by quieting the cough reflex in the brain rather than addressing mucus or airway size.

How should Grilinctus-BM be stored and disposed of?

Storage Requirements

Official labeling mandates that Grilinctus-BM Syrup and Tablet must be stored below 25 C in a clean and dry place. The medicine requires protection from light and direct heat to maintain its stability. It must be kept in the container or pack it came in, and the cap must remain tightly closed at all times.

Child-Safety and Disposal

A critical requirement is to keep the medicine out of the sight and reach of children and away from pets to prevent accidental ingestion. Regulatory documents stipulate that any unused or expired medicine must be disposed of properly. Disposal must ensure that the product is secured and not consumed by people or pets, aligning with official guidelines for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

India

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z